Study S000055

A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin

ClinicalTrials.gov record

Registration

Registration: NCT01664624
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 40
Start: 2012-07
Primary completion: 2012-11
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:Roflumilast; DRUG:Alogliptin; DRUG:Exenatide; DRUG:Placebo to roflumilast; DRUG:Placebo to alogliptin
Results posted: TRUE
Secondary identifiers: REGISTRY:U1111-1128-6945

Registered primary outcomes

Change From Baseline in Postprandial Area Under the Curve From Time 0 to 8 Hours (AUC[0-8]) for Active Glucagon-like Peptide-1 [Baseline and Day 11; samples were taken at -15 min and -5 min (pre-meal), and 15 min, 30 min, and 1, 2, 3, 4, 6, and 8 hours (post-meal).]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.